Schedule of Restricted Stock Unit Activity (Details) - USD ($) |
12 Months Ended | |
---|---|---|
Dec. 31, 2023 |
Dec. 31, 2022 |
|
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Shares, Released | (545,012) | |
Restricted Stock Units (RSUs) [Member] | ||
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] | ||
Shares outstanding, Beginning balance | 1,929,933 | 1,685,141 |
Balance, exercise price | $ 1.04 | $ 1.18 |
Balance, aggregate intrinsic value | $ 2,018,811 | $ 1,180,407 |
Shares, Awarded | 414,104 | 244,792 |
Awarded, exercise price | $ 0.63 | $ 1.06 |
Awarded, aggregate intrinsic value | $ 260,886 | $ 260,579 |
Released, exercise price | $ 1 | |
Released, aggregate intrinsic value | $ (588,613) | |
Shares outstanding, Ending balance | 1,799,025 | 1,929,933 |
Balance, exercise price | $ 0.94 | $ 1.04 |
Balance, aggregate intrinsic value | $ 1,691,084 | $ 2,018,811 |
Shares, Expected to vest at December 31, 2023 | 1,799,025 | |
Vested, aggregate intrinsic value | $ 1,691,084 | |
Unvested | ||
Unrecognized expense |
X | ||||||||||
- Definition Share based compensation arrangement by share based payment award equity instruments other than options awarded aggregate intrinsic value. No definition available.
|
X | ||||||||||
- Definition Share based compensation arrangement by share based payment award equity instruments other than options awarded aggregate intrinsic value released. No definition available.
|
X | ||||||||||
- Definition Share based compensation arrangement by share based payment award equity instruments other than options grants in period weighted average grant date fair value released. No definition available.
|
X | ||||||||||
- Definition Share based compensation arrangement by share based payment award equity instruments other than options outstanding aggregate intrinsic value. No definition available.
|
X | ||||||||||
- Definition Share based compensation arrangement by share based payment award equity instruments other than options vested aggregate intrinsic value. No definition available.
|
X | ||||||||||
- Definition Share based compensation arrangement by share based payment award non option equity instruments vested and expected to vest outstanding number. No definition available.
|
X | ||||||||||
- Definition Sharebased compensation arrangement by sharebased payment award equity instruments other than options outstanding weighted average exercise price. No definition available.
|
X | ||||||||||
- Definition Amount of cost not yet recognized for nonvested award under share-based payment arrangement. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
X | ||||||||||
- Definition Number of non-option equity instruments exercised by participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Net number of non-option equity instruments granted to participants. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Definition Number of equity instruments other than options outstanding, including both vested and non-vested instruments. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
X | ||||||||||
- Details
|